UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington,
D.C.
|
Delaware
|
0-9314
|
83-0221517
|
(State
or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS
Employer
Identification No.) |
2600 Stemmons Freeway, Suite
176
Dallas, Texas |
|
75207
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant's telephone number,
including area code:
|
(214) 905-5100
|
|
|
(Former
name or former address, if changed since last report)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
|
x
|
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
|
/ /
|
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
/ /
|
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
/ /
|
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
SIGNATURES
|
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
ACCESS PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Stephen B. Thompson
|
|
|
|
|
|
|
Stephen B. Thompson
|
|
|
Vice President, Chief Financial
Officer
|
|
Date: June 16, 2009
|